Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
February 6, 2020
Earnings Call Speaker Segments
Nick Rolli
executiveGood day, and thanks for being here with us. We put out a press release earlier today that lays out all the specifics regarding how we performed in the fourth quarter of 2019 and across that entire year. That document is available at www.pmi.com, and you can also find it through the PMI Investor Relations App. A glossary of terms — this covers what we mean by reduced-risk products, or RRPs, along with adjustments, other calculations and reconciliations to the most directly comparable U.S. GAAP measures, plus our business transformation metrics — appears at the conclusion of the webcast slides for today, and those are up on our site. Except where noted, whenever we mention IQOS, we're referring to our heat-not-burn offerings under that brand. All comparisons use a like-for-like basis, reflecting pro forma 2018 results, which were adjusted for the deconsolidation of our Canadian subsidiary, Rothmans, Benson & Hedges, Inc., effective March 22nd, 2019. Remarks today include forward-looking statements and projections of future results. Please turn your attention to the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could cause actual results to differ materially from projections or forward-looking statements. At this point, it's my pleasure to bring in André Calantzopoulos, our Chief Executive Officer. Martin King, our Chief Financial Officer, will be with André for the question-and-answer session. André?
André Calantzopoulos
executiveAppreciate it, Nick. Good morning, everyone. Looking at 2019, the numbers kept showing solid fundamental momentum coming out of both the combustible side and the smoke-free side of the house. Across a wide spread of geographies, IQOS keeps delivering strong results, and we remain solidly positioned to hit the 2021 target for heated tobacco unit shipment volume — somewhere between 90 billion and 100 billion units. At the same time, the combustible side of things keeps chugging along nicely, supported by dependable pricing. We crossed a number of significant thresholds on the road to a smoke-free future. In particular, a version of IQOS got the green light from the U.S. Food & Drug Administration via the pre-market tobacco product application route, and after that we brought it to market commercially in Atlanta and Richmond through the licensing arrangement we have with Altria. These days, IQOS can be bought commercially in 52 markets around the globe. Now I'd like to walk you through the key pieces of our full-year numbers, beginning with volume. Total industry volume for cigarettes plus heated tobacco units fell 2.0%, which is pretty much in keeping with the long-term pattern and a touch ahead of the roughly 2.5% we'd projected earlier. Our shipment volume came down 1.4%, matching the 1% to 1.5% decline we'd told you to expect. What drove the industry outperformance was heated tobacco picking up 0.6 points of share, which cushioned the drop in cigarettes — a drop that was partly the result of cannibalization by heated tobacco units. Turning to the fourth quarter, I want to point out that although inventory movements didn't matter much over the whole year, the steeper 4.4% shipment volume decline in Q4 2019 is partly a reflection of adverse combustible cigarette inventory movements amounting to 2.3 billion units versus the same quarter a year earlier, especially in the European Union region and Japan. We expect this to partially reverse in those geographies during the first quarter of 2020. In-market sales volumes for the fourth quarter were down 3.1%. Like we told you during the third quarter call, the decline in in-market sales is largely attributable to what happened with pricing in Turkey and the Philippines. When it comes to Turkey, two rounds of price increases during the year — April and August — were the main driver behind the drop in cigarette volume, totaling five Turkish Lira per pack, which works out to 44%. Because of how our pricing timing lined up against competitors, our share took a bigger hit than the industry decline alone would explain. Our share did improve sequentially over the course of Q4 2019, though the market as a whole remained weak because more illicit cut tobacco was being consumed. In the Philippines, the drop in our cigarette volume mostly mirrored a smaller total market right after industry price increases. Still, from a volume/mix standpoint, Marlboro's strong share performance partly made up for it. Heated tobacco unit shipment volume rose 44% to 60 billion units in 2019. That performance, which included shipments surpassing 17 billion units during the fourth quarter, shows widespread gains throughout our launch markets, with significant input from the EU Region, Japan and Russia, and it keeps us firmly positioned to hit our 2021 shipment volume goal of 90 billion to 100 billion units. Thanks to this outstanding result, heated tobacco units now represent almost 8% of our overall shipment volumes, versus virtually nothing back in 2015. We expect that share to continue climbing, because the favorable trend for our lower-risk offerings remains in place. Turning to how we performed financially in 2019, net revenues climbed 6.4% on a currency-neutral basis, driven by strong pricing across our combustible product lineup and by growth in heated tobacco units. RRP net revenues reached $5.6 billion, which works out to almost 19% of PMI's overall net revenues, while IQOS devices accounted for about $0.7 billion, equal to 13% of RRP net revenues. As we mentioned before, this lower proportion of device revenues chiefly reflects a beneficial geographic blend of heated tobacco unit volume, the extended useful life of the newest IQOS devices, and the impact of changes to device retail prices in certain markets. In 2019, our pricing for combustible tobacco came in at a 6.5% variance, which was a solid result and exceeded what we had originally forecast for the year. A generally sensible environment for excise taxes and competition helped make that possible. Beyond the pricing already mentioned in the Philippines and Turkey, we saw meaningful gains from Germany, Indonesia and Russia. Since the 2008 spin, this was in line with the typical historical variance. Adjusted operating income rose 11.2% when measured on a currency-neutral basis, and adjusted operating income margin grew by a very strong 170 basis points. That margin growth came from scale effects in RRP as well as a favorable geographic mix for the heated tobacco unit. Other things pushing us forward are the way we price combustibles along with what our cost programs are delivering. We remain solidly on schedule to deliver more than $1 billion in efficiencies by 2021, and that money helps fund growth investment behind RRPs. Speaking of which, during 2019 we rolled out the full $400 million of planned incremental RRP investment, with the net rise in spending partly offset by bigger efficiencies we captured through our broader cost program. Adjusted diluted earnings per share climbed sharply, up 9.9% once currency is excluded, which beat the roughly 9.5% we had guided to earlier. As we discussed in the third quarter results, the softer currency-neutral gain in adjusted diluted earnings per share relative to adjusted operating income comes down to higher non-controlling interest and a higher like-for-like tax rate. We generated $10.1 billion in operating cash flow, which was a $0.6 billion increase. That improvement came thanks to several working capital efforts as well as the way certain cash costs tied to optimizing our Berlin factory fell on the calendar. Turning to capital spending, we finished at $0.9 billion, slightly below the approximately $1 billion figure we'd projected for the entire year, and the difference resulted from production efficiencies. Moving now to market share, our overall international share climbed 0.1 point to 28.4%. A drop in cigarette share, which reflects cannibalization, was outweighed by an increase in heated tobacco units, and that category reached 2.2%. Within our cigarette portfolio, share fell 0.5 points, a reflection of adult smokers continuing to switch away to IQOS, especially in the European Union Region and Japan, along with weaker share in places like Argentina, Indonesia, Korea and Turkey. Even with that switching away, Marlboro still lifted its portion of the cigarette category by 0.3 points, hitting a record 10%, powered by Indonesia, the Philippines, Saudi Arabia and Turkey. Commercially, IQOS is now on sale in 52 markets, which equals 44% of the entire international market, and inside those markets our weighted-average geographic coverage sits at roughly 60%. That comes after we added 8 new markets during 2019, among them Hungary, Sweden, the United Arab Emirates and the United States, plus a fourth quarter launch in Mexico, at first concentrated in chosen areas, of Mexico City. Later in the year we made another significant move on the path to a smoke-free future by introducing IQOS 3 DUO, which today is sold in every one of our international IQOS markets, backed by our new Simply Amazing brand campaign. That Simply Amazing campaign highlights ordinary, relatable moments and feelings, showing adult smokers who would otherwise keep smoking what they gain by switching to IQOS. This newest member of the IQOS family was built with improved features so adult smokers can switch over from cigarettes more smoothly.
André Calantzopoulos
executiveWith IQOS 3 DUO, you get two back-to-back sessions before the holder needs charging, and its recharge time is much quicker than that of IQOS 3 and IQOS 2.4 PLUS. The early signs from the DUO roll-out have been favorable when it comes to conversion rates and how satisfied consumers are, which gives us confidence about how consumers are responding to innovation as we enter 2020. We keep cultivating a robust pipeline of upcoming enhancements and innovations for the core IQOS platform. Now let's dig deeper into how RRP performed. Our estimate is that close to 14 million people were using IQOS in total at year-end, which means four million adult users were added across the year. Given the momentum we currently have, we anticipate that this pace of acquisition will rise substantially in 2020. Our estimate further shows that 71 of the total — almost 10 million IQOS users — have quit smoking and moved to IQOS, while the remainder are at various points in the conversion process. This mirrors broad-based user expansion, with notable points being an almost doubling of users in Italy and Germany, an almost trebling in Poland, really robust growth in Ukraine, and 1.7 million users added in Russia, bringing the total there to 2.5 million. Now let me walk you through how IQOS did in 2019. On overall share performance, IQOS heated tobacco units keep making superb progress. In fact, across international markets where IQOS has been launched, IQOS heated tobacco units ranked as the third biggest tobacco brand during the fourth quarter, with a 5.5% share, up from the number four spot in the third quarter. That was accomplished even though full national distribution is still lacking in quite a few markets, as I noted earlier. IQOS's ongoing superb growth mirrors advances across a wide array of markets. Our commercialization strategy begins by concentrating on the key cities — the key cities inside a market — to build adult smoker awareness, trial and conversion. On this slide, we can see the powerful off-take share momentum across a number of key cities. That gives us even more confidence regarding potential future growth at the national level, as we observe gains in both our geographic reach and in rates of consumer awareness and trial. Within the EU region, HEETS's fourth quarter share came to 3.2% of total cigarette and heated tobacco unit industry volume, a rise of 1.5 points — or nearly double — versus the fourth quarter of 2018. Looking sequentially, share growth sped up during the quarter, rising 0.7 points. In-market sales volume also climbed 16.1% versus the third quarter of 2019. This expansion mirrors sustained strength across a wide array of markets, as laid out on this slide. Worth keeping in mind is that IQOS is present only in geographic areas that account for roughly 57% of industry total volume in the region. Consumer acquisition quality is high as well, with conversion rates and registration rates getting better as time goes on. In Russia, IQOS kept up its robust results during Q4. HEETS' portion rose 3.3 points, hitting 5%. Looking at it quarter over quarter against Q3, HEETS' portion went up one point, and sales within the market climbed more than 20%, arriving at 2.9 billion units. The expansion in HEETS' portion during the quarter matched how quickly adult smokers were taking it up along with how far our geography had spread; at this point we're selling IQOS in cities that account for roughly half the market based on overall industry volume, versus an estimated 40% when Q2 ended. When it comes to Japan, the total share we reported for heated tobacco units climbed 2.4 points, reaching 17.6% in Q4, helped along by rolling out IQOS 3 DUO plus line extensions across a Marlboro HeatSticks and HEETS line-up. As we've noted before, overall industry and share figures in Japan right now are somewhat skewed because of the low price cigarillo segment, which expanded quickly across the last two quarters, getting to a total tobacco share of 6% in December; such products currently get significantly preferential tax treatment, even though the ruling party's tax council recently said it would close that gap through two steps, one in October 2020 and another in October 2021. Although this segment's expansion will probably be short-lived, we intend to launch under the Philip Morris brand during the current quarter so we can grab our fair share. Looking at total tobacco, cigarillos included and with trade inventory movement adjusted for, the share held by our heated tobacco unit brands went up 1.5 points against the same quarter last year and 0.6 points quarter over quarter, landing at 16.9%. During 2019, in-market sales volumes for heated tobacco unit brands rose 4.2% against a total tobacco market, cigarillos included, that fell just over 3% once you adjust for the estimated effect of trade inventory movements. That assisted in pushing the whole heated tobacco category's growth to a Q4 total tobacco share of nearly 24%, cigarillos included and adjusted for trade inventory movements. In Korea, the heated tobacco category still feels a lingering effect from consumer confusion stemming from the Korean FDA's 2018 communication regarding tar. Competition in the category also stays intense, especially around non-menthol flavors and the related new taste dimensions that exist in the cigarette category too. HEETS' portion in Q4 dropped 2.2 points, or 1.4 points on an adjusted basis. Still, quarter over quarter, the adjusted share for Q4 was basically flat, and our segment share kept expanding, backed by IQOS 3 DUO and recent launches that broadened the flavor line-up. Though this trend gives us encouragement, plenty of work remains for us to strengthen the heated tobacco category's advantages and further build on IQOS' leading position. One major 2019 milestone was bringing IQOS to the U.S. via our commercial arrangement with Altria. Our first IQOS brick-and-mortar locations have now launched in Atlanta and Richmond — those being the two original debut markets — and that represents a landmark moment in our push to give the 40 million American men and women who still smoke something better. It's still very early in terms of commercializing that lead market, but the size of the prize has us excited. Just to remind everyone, IQOS holds the distinction of being the sole heat-not-burn offering currently authorized for sale in the U.S. by the Food and Drug Administration, which makes the PMTA route the right fit when it comes to protecting public health. In the months ahead, we intend to pursue one more marketing order, this time for the IQOS 3 device, and that will give further backing to our work converting American adult consumers who would keep smoking otherwise. With our heated tobacco lineup performing well, we intend to bring our e-vapor offering, IQOS MESH 2.0, to market within this year. After consumers got confused about e-vapor toward the end of 2019, we chose to push back the first commercial launch. Sadly, those mistaken impressions, even though they are easing, haven't gone away, so our plan now is to roll out during the third quarter of this year, which is also when we'll have the capacity we need to deploy at scale. Consequently, we intend to speed up the commercial rollout more quickly across the back half of 2020. It's worth taking a moment to think about how the international e-vapor market works, since that's where IQOS MESH 2.0 will compete.
André Calantzopoulos
executiveThe business we have today leans very heavily on a small number of regions. Of the roughly 25 million adult users of international products, about 70% are located in 10 markets. That group of users is close to double the size of heated tobacco's, and yet it brings in less than 50% of the retail value that heated tobacco generates. What explains this is a pronounced skew toward open tank systems, limited product differentiation, and a low rate of full switching relative to heated tobacco products. Among those 10 markets, seven also set a significant limit on nicotine concentration. IQOS MESH was designed with exactly this backdrop in mind, and it can leverage our existing RRP commercial infrastructure and capabilities to drive consumer trial and repeat purchase. Taking everything together, we believe IQOS MESH will deliver a superior experience and drive further growth in our business as we move ahead. Now to the commercialization outlook for RRPs: we announced not long ago a global collaboration agreement with KT&G to commercialize their smoke-free products outside Korea. The primary rationale for this deal is to accelerate growth of the smoke-free category, and achieving that requires multiple products that give adult smokers a wide range of brand, taste, price and technology options. Our RRP capabilities—covering commercial infrastructure and know-how, technology, scientific substantiation and regulatory engagement—are best-in-class. We can put them to work broadening our strong portfolio and innovation pipeline, advancing category growth further, including via partnerships with others whenever that makes strategic and economic sense. KT&G's portfolio of smoke-free products looks to us to be complementary to our own. Under this agreement we are responsible for all elements of commercialization of product supply, and we intend to roll out on a market-by-market basis. The initial term of the deal is three years, with the goal of expanding the market footprint subject to commercial success. We don't disclose the financial terms of such an arrangement, but it is royalty based. Any products sold under the agreement will be carefully assessed to confirm they meet regulatory requirements in the markets where they launch, as well as PMI's high standards of quality and scientific substantiation of their harm reduction potential. We are currently working toward first launches later this year. There are no current plans to commercialize KT&G products in the United States. Thanks to this deal, plus our own IQOS MESH rollout in 2020, we've got a busy and thrilling year in front of us. Now, on to our 2020 guidance: we're projecting reported diluted earnings per share of no less than $5.50, using prevailing exchange rates, which compares with reported diluted earnings per share of $4.61 for 2019. On a like-for-like basis, and leaving out an unfavorable currency hit of roughly $0.04 at prevailing exchange rates, that forecast works out to a projected gain of at least 8% against pro-forma adjusted diluted earnings per share of $5.13 in 2019. As for how this breaks down by quarter, we anticipate EPS growth and net revenue growth will be especially robust in the first quarter, then noticeably weaker in the second quarter of 2020. We expect the total industry measuring 370 billion units in 2019 to decline by around 6% to 7% in 2020. During the first quarter, we benefit from how pricing is timed in the Philippines, plus an easier comparison against the first quarter of 2019, when Turkey absorbed a significant excise tax increase. Conversely, results in the second quarter will likely be pressured by two things: a difficult comparison to a robust second quarter of 2019 and the most severe effect of tax-related pricing in Indonesia. Another point to note is that our greater weighting toward growth in markets where non-controlling interests are substantial, something observed during the latter half of 2019, will persist into the first half of 2020 owing to annualization effects. Let me now go through the Indonesia situation in greater detail. As we said back in December, this is an atypical year of catch-up on both excise tax and pricing for the industry. Excise tax for 2020 took effect on January 1st, bringing a weighted-average industry-wide excise tax increase of 24%, together with a 46% rise in the minimum banderole price. Even though the possible tax pass-on is rather steep, at 14% of the weighted average price, viewed across a two-year stack, given that 2019 had no excise tax increase, the average percentage increase is broadly in line with what we've seen historically. The tax increase and the higher banderole price should also provide an opportunity to correct the price gaps that damaged our share performance in 2019. So far, between October and January, we've announced pricing of 8% on a weighted-average basis, representing roughly 60% of the pass-on. As of today, some competitors are lagging on pricing and will require a larger catch-up to reach the new minimum retail price that takes effect on April 1st. We should also highlight the one-time impact on our pricing variance caused by the absence of any excise tax increase in 2019. Since we implemented minimal pricing during the first nine months of last year, the typical annualization benefit from increases taken in the prior period won't materialize this year; that atypical dynamic essentially creates a one-off hit to our 2020 pricing variance that exceeds $200 million. As we've previously stated, we expect the total industry — which came in at 307 billion units during 2019 — to decline by approximately 6% to 7% in 2020, with the brunt of the impact likely falling in the second quarter, once the new minimum retail selling price takes hold and new prices work their way through the trade. With pricing resuming this year, we anticipate market dynamics will improve in 2021. Our 2020 guidance is based on several key assumptions. The largest, as just noted, is the pricing rollout in Indonesia, which we currently assume will reduce our combustible pricing variance to about 5% in 2020. While that's lower than our 2019 pricing variance, it remains quite strong and is supported by an excise tax environment that is generally rational. Taking into account what we project for the whole market in Indonesia—a drop of 6% to 7%—we're currently taking the cautious position that currency-neutral net revenue will grow roughly 5%. Even so, let me say again how strongly confident we remain in our guidance calling for currency-neutral earnings per share growth of no less than 8%. A key driver of that confidence is the favorable margin picture; our efforts to achieve over $1 billion in annualized cost efficiencies by 2021 are bearing fruit, spearheaded by significant initiatives related to productivity, managing cost categories, a project-based organization model and further cost efficiencies. Looking at 2020, we anticipate that cost efficiencies will completely counterbalance the net incremental RRP investments we expect. Because our RRP business keeps expanding in scale and geographic footprint, the added investments today largely consist of variable costs connected to bringing in new consumers and keeping current users, along with entering new markets. Consequently, cost per user is trending better, and we project a 25% decrease in our acquisition cost per user in 2020. We anticipate that greater leverage from our commercial platform will assist in pushing up currency-neutral operating income margin by no less than 150 basis points in 2020. Now for the industry volume picture: our estimate for total market decline this year sits at approximately 3.0% to 4.0%. While that is softer than the 2.0% to 3.0% historical average, it closely reflects the short-term circumstances in Indonesia, a market representing roughly 11% of total industry volume. Separately, for the total industry, we're looking at 370 billion units in 2019 and expect a decline of around 6% to 7% in 2020.
André Calantzopoulos
executiveAnother element stems from the fact that cigarillo sales are currently expanding in Japan, and that segment isn't part of the overall cigarette market figures. As the chart illustrates, our assumption of a 6% to 7% decline in Indonesia should drag roughly 0.7 points off the worldwide industry, plus another 0.3 points tied to Japanese cigarillo growth. Beyond the normal pluses and minuses seen elsewhere, those two short-term effects together account entirely for the gap versus the long-term average, while the underlying fundamentals stay the same. One more forthcoming change baked into our industry outlook is the EU's Tobacco Products Directive prohibition on menthol cigarettes, which takes effect May 2020. Roughly 10% of consumption in that region consists of menthol and menthol capsule versions. Although we don't anticipate much of an effect on the overall industry volume decline of 1% to 2%, IQOS stands to gain further, since menthol HEETS variants fall outside the ban's scope. For 2020, we expect PMI shipment volumes to once more beat the industry trend, with an anticipated drop of about 2.5% to 3.5% across total cigarette and heated tobacco unit shipment volume; thanks to the dynamics already discussed in Indonesia and Turkey, our shipment volume trends should be somewhat stronger in the second half than in the first. Though no specific 2020 target for heated tobacco unit shipment is being given, we foresee continued broad-based growth and remain firmly on course to hit our shipment volume goal of 90 billion to 100 billion units by 2021. We expect a full-year effective tax rate near 23%, in line with last year, along with net interest expense that is fairly stable versus 2019. Our 2020 operating cash flow goal is about $10.5 billion, depending on year-end working capital needs and currency fluctuations. That figure includes the anticipated one-time hit from new excise payment rules in Australia, plus the timing of certain cash costs tied to the Berlin factory restructuring. Those two items together produce an expected unfavorable cash impact of roughly $350 million. We estimate total capital expenditures for this year at about $1 billion. To sum up a strong year, we achieved very substantial progress in transforming toward a smoke-free future, both within our organization and in our 2019 business results. A little more than four years after the first full-scale IQOS commercial launch in Japan in September 2015, we already hold $5.6 billion in RRP net revenues, which represent nearly one fifth of our business. Crucially, RRP revenues keep becoming more accretive to our profits, as shown by the robust margin growth in 2019 and the growth anticipated in 2020. IQOS keeps up its strong momentum, with in-market sales volumes for HTUs rising 35%, driven by a growing list of countries where nearly 10 million adult smokers have already quit cigarettes and made the switch to IQOS. For 2020 overall, we expect the count of new users to come in well above what we saw in 2019, while the cost to acquire each user will be smaller, since most of the big RRP infrastructure spending from recent years is now behind us. We're also sharply focused on keeping our combustible tobacco business in the leading position, and it's turning in solid results along with strong pricing power. Even with the short-term pressure in Indonesia, our 2020 guidance is something we feel good about, and we're still firmly on course to hit the 2019 to 2021 compound annual ex-currency growth targets: no less than 5% growth in net revenue and no less than 8% growth in adjusted earnings per share. Last, our confidence in the smoke-free future strategy is strong, and we're certain that the RRP portfolio we have today and will have tomorrow remains our biggest single chance to speed up business growth and reward shareholders generously over the long run. Thank you. Martin and I are now happy to answer your questions.
Michael Lavery
analystThank you. Good morning.
André Calantzopoulos
executiveHi, Michael.
Martin King
executiveGood morning.
André Calantzopoulos
executiveGood morning.
Michael Lavery
analystMichael, could you speak to IQOS and what’s happening at what are really two opposite ends of the adoption curve? Take a market such as Hungary — it gained more than four share points in only 12 months, seemingly from nothing — yet you’ve also referred in the past to lower acquisition costs per user, which come from scale and from word of mouth expanding. I’d really like to grasp both of those dynamics a bit better. First, in certain markets, what are you doing to produce such fast uptake? Second, once things mature somewhat, which main factors create your efficiencies?
André Calantzopoulos
executiveRight. As an organization that learns, each time we enter a new market, we take what the last one taught us and put it to use. That means the period before we begin accelerating gets briefer and briefer. I believe we presented a chart along these lines not long ago, and next week at CAGNY we’ll go through it. So we are a learning organization. Rolling out additional digital capabilities means each market we newly enter begins expanding more quickly than the one before it — that’s simply a matter of organizational knowledge. Since our infrastructure is now also established, the cost for each user will drop, and it is dropping in 2020; we need to put somewhat more money into retention. That said, retention costs ought to fall too, since our base of people is larger. Obviously, acquisition costs run higher, which makes sense; with sufficient people now in our CRM base, putting a bit more there is logical, because by definition losing a consumer we already gained is a far greater loss than failing to gain one. Also, with digital infrastructure in place, we can gradually widen the offering past accessories, special editions, and standard products toward additional items that help us build a different kind of business over time, given the data we hold on consumers. So I remain optimistic that, even though we’ll keep investing incrementally in RRP, Michael, to increase our user count, the cost for each user will continue declining further and further, and clearly we hold on to more consumers, so all of that is favorable — that’s how I view it. Did that answer it?
Michael Lavery
analystNo, that helps a lot. Thanks. Let me ask one brief thing that builds on that. If you consider how IQOS consumption habits have developed, the charts you've presented indicate that roughly 70% of those users end up switching over completely on a consistent basis. But clearly, you keep bringing in fresh users too, and those people have clearly only just begun. How long does it usually take someone to make that change — or, to put it another way, for somebody who started with the product, let's say 1 or 2 years back, would the share who've completely switched be closer to 75%, 80%, or 85%? How should we interpret that pattern?
André Calantzopoulos
executiveFor people who are new, plainly, the typical figure we cite is 2 weeks up to 1 month, varying by person; occasionally someone needs far longer before making a complete switch. Right; they begin using it right away of course, since they've paid for it. As for keeping users over time, I'd describe it as quite steady, and my expectation is that the fresh initiatives inside our CRM will lift that retention. It also varies by market, as you're aware. In places where rivals are very active, we see some thinning of consumption, since consumers purchase alternative devices, usually far less expensive ones from competitors, and sample several products; yet when I look at markets where competitors haven't yet found success, I'd say retention is quite strong, and I believe we can boost it further now that we're rolling out an improved CRM program across the year. So what we've got makes me quite pleased, and there's room to do better going forward.
Michael Lavery
analystThat's excellent. Many thanks.
Robert Rampton
analystHi there. I've got three questions. First one would be: apart from Korea and Japan, is there anywhere else where IQOS shipment volumes have fallen quarter over quarter, and conversely, are there any places where quarter-over-quarter expansion has sped up?
André Calantzopoulos
executiveAll right. What I'd say is that, leaving Korea aside, every market is growing for us. Right. Korea is a unique case, since there's consumer misunderstanding surrounding the heat-not-burn segment, quite similar to what took place in numerous markets with the e-vapor segment, and that took place at the start of last year, in June, when the Korean FDA, despite having discovered a very substantial drop in the toxicants of heated tobacco product versus cigarettes, quite close to what we've reported, they sort of muddled consumers by stating yes, but this product's tar is very close to that of cigarettes, even though we're comparing apples with oranges, since there are two distinct pathways. One involves water and glycerin, while the other involves chemicals. So that has put the category on hold, and I believe it'll take some time before the process can restart. I believe eventually the authorities in Korea will realize that isn't the correct approach with consumers, and the alignment we now have, much stronger with KT&G following the agreement, I think they'll assist in growing the category, but aside from Korea, I don't see anywhere else where we have a problem.
Robert Rampton
analystOkay, and regarding the improvement in margins—when we consider your outlook for 2020, how much comes from things like cost reductions, pricing, and IQOS? Would it be reasonable to assume that IQOS's effect gets balanced out by savings on costs plus the added price hikes, or is there another way we should look at it?
Martin King
executiveYes, several elements are behind the margin gain. To start, some of it relates to mix, since we're now expanding at a very fast pace in the EU, where margins are quite strong for IQOS through tobacco units. The next thing is, as you mentioned, we've really ramped up our efforts to cut costs. Right now, those cost-reduction programs completely cover what we're spending on RRP, and that's what drives the sizable gain in margin. Those savings come from a few different areas. On the operations side, we're seeing a range of productivity gains — particularly as we grow more proficient at making the consumables for heated tobacco units at greater volume, and as we get less waste and more uptime from the machinery. We're also making the overall manufacturing footprint more efficient. You're familiar with the factory improvements we made over the past year, and those are starting to deliver results as we move into 2020 and later. Beyond that, we've got programs in place throughout every spending area aimed at finding smarter ways to gain efficiency, shifting resources away from places that aren't performing as well, and redirecting them toward products with lower risk. That entire push began showing benefits during the past year — you'll recall our margin growth was quite robust, up 1.7 percentage points — and for this year we're targeting an increase of no less than 1.5 percentage points. We'll keep our attention on this in future years as well.
André Calantzopoulos
executiveYes. On the topic of pricing, like I mentioned, our expectation is that it will come in slightly under what we saw this year compared with 2019, and really that comes down to Indonesia. The reason is that back in 2019, we benefited from the annualization of 2018 pricing in Indonesia, and right now we're assuming that won't repeat. Clearly, since there wasn't any meaningful pricing in 2019, you get no annualization effect in 2020, and we need to stay somewhat careful about pricing and the way it plays out in Indonesia, given there's quite a sharp increase. That said, our assumption is this will get sorted out over the course of 2020. As a result, in 2021 we'll see annualization of pricing in Indonesia and things return to normal.
Robert Rampton
analystGreat, and sorry about that. I just have one more question: when it comes to IQOS operating margins, could you share a bit of detail on how they stack up against cigarettes — for example, in Italy on one side and Russia on the other?
André Calantzopoulos
executiveSure, IQOS margins come in above those for cigarettes. All right, so that much is basically straightforward, and as Martin described, a substantial portion of the margin gain is essentially being driven by IQOS.
Robert Rampton
analystAll right, thanks a lot.
Vivien Azer
analystThanks. Morning to you.
Martin King
executiveHi there, Vivien.
Vivien Azer
analystYou all clearly come across as quite optimistic about the momentum behind IQOS. I was hoping you might address what your main rival said this morning regarding the RRP category in Japan. To be specific, their perspective may differ from yours — they indicated they expect more moderate growth, aiming to reach 25% of industry volumes as competition heats up. Could you respond to that?
André Calantzopoulos
executiveAt this point, I think it's quite hard to say what the exact growth of the category will be. Perhaps my view is higher than theirs, but both of us foresee growth, and that's what matters most. And I believe we're well positioned, given all the initiatives we have in place, to capture the biggest portion of that growth. So we'll see how the year plays out and where exactly we land, but the crucial point is that we stay focused. IQOS continues to hold a lion's share of the segment, and the momentum is positive and accelerating. We're growing both segment share and overall market share. So that's the key thing to retail.
Vivien Azer
analystGreat, that's useful. One more question about Japan. Could you share any detail on how your HTU mix breaks down between HEETS and Marlboro when 2019 came to a close?
André Calantzopoulos
executiveI can't recall the precise figures offhand, though I'd describe cannibalization as steady; following the price rise, there was, let's say, some down-trading, since Marlboro's prices went up by more than HEETS did, yet things have now settled again and each brand is expanding, with Marlboro, once more, on the rise.
Martin King
executiveI think, Vivien, we haven't given the exact split.
André Calantzopoulos
executiveYeah.
Martin King
executiveStill, I believe we can safely state that Marlboro's portion—specifically the share held by Marlboro HeatSticks—wound up exceeding what we'd initially anticipated. We'd figured HEETS would represent a larger piece at this point, and Marlboro HeatSticks has proven more resilient than we'd assumed, considering the pricing. Conversely, HEETS fulfilled its role of growing the category and bringing the offering within reach of a wider set of consumers who were more sensitive to price. So this result satisfies us, and on the whole it accomplished what it needed to. That said, a greater number of heated tobacco users chose to remain with Marlboro HeatSticks than we'd initially intended, which naturally benefits our margins and our profitability.
Vivien Azer
analystOf course, definitely. That's a fantastic result. One final question from my side. André, I really valued what you had to say regarding a few of the e-vapor worries that appear to be extending into the EU. That definitely matches what we heard yesterday from one of your rivals. Should we be keeping an eye on any major markets, especially those where consumer anxiety or uncertainty about e-vapor danger is becoming most severe?
André Calantzopoulos
executiveWell, I believe the peak came following those tragic U.S. incidents involving the lung illness and fatalities, which certain individuals interpreted in an incorrect manner. As you're aware, I think things are improving, yet we haven't reached the finish line, since some people continue to sow confusion in spite of all the work that I and others are doing to clarify that this is unrelated to the e-vapor sector and instead tied to misuse involving cannabis, oils and so forth. My — our view on this was that regardless, our e-vapor strategy involved creating the capacity and entering the majority of the market, which is the European Union, around the close of the year, all right, since at that point we'd have capacity at scale. We had intended a handful of markets sooner on a trial basis. I think it's wiser not to add fuel to the fire, particularly given that we'll place the e-vapor beneath the IQOS brand. So to reduce confusion, I'd rather allow a bit of time to pass. We build capacity and it doesn't actually alter our plan for the European Union, which was around the end of this year. So that's how I see it. And I think the moment has come for more voices to speak up and stop misleading people, and I was reading the latest Q&A from the World Health Organization and that's not my own commentary, but there is so much misleading and, I'd say, malicious content in it that some of the leading public health advocates came forward and declared this is unacceptable. So they revised their version, yet they're still misleading. So I think in the near term that might not look like a positive thing, but over the long run, the more people utter absurd things, the more credibility they forfeit and the more the alternatives will gain credibility because they lose theirs; and I think we're at that stage right now where, honestly speaking, you see more and more of this nonsense and more and more voices saying let's put a halt to this, have I reset now of the situation and stopped talking seriously because these alternatives are better for people who would otherwise smoke. But regarding the commercial side, that's all — that's why, it's what I stated and what I just explained. Hope I'm clear.
Vivien Azer
analystThat's quite clear. Thanks a lot.
Adam Spielman
analystHi, and many thanks for fielding the question. Since Vivien brought up Japan, may I pose just one brief item on that before we move to IQOS? What I'd like to know about Japan is whether, within your price variation, you are incorporating any presumption regarding the tax increase we clearly are set to see in October of this year — that's my first question.
André Calantzopoulos
executiveWell, Adam, all pricing is obviously reflected in the guidance. So whenever we anticipate a chance in Japan, at moments when a tax hike occurs, to secure pricing, we'll build in certain assumptions, and we'll observe the degree to which those come to pass or not.
Adam Spielman
analystGreat, that's extremely clear. So the key issue, the main issue, clearly concerns IQOS, and beginning with Europe — starting with the European Union — during Q3 you saw market share rise 0.1% quarter over quarter, and after that came far stronger, truly impressive growth in Q4. And I was simply asking how you believe we ought to view EU market share moving ahead, whether seasonality plays any role there, and how you think those two things should be evened out — somewhat underwhelming from my perspective in Q3, followed by such a robust result in Q4?
André Calantzopoulos
executiveAll right. Broadly speaking, seasonality certainly exists in summer, and obviously it benefits cigarettes, which means somewhat lower market share for the heated tobacco unit. Secondly, even though IQOS felt only a slight impact from the entire e-vapor circumstances in the U.S., right at that point in the quarter we experienced something of a September slowdown, I'd say, yet we bounced back by October/November, and my sense is we're heading into 2020 carrying solid momentum. The user count keeps rising. As I mentioned, menthol, I believe, gives us an opening during the year's second half. So regarding momentum and results in the European Union, I feel quite optimistic.
Adam Spielman
analystSo, to put it briefly, my take is you're indicating that 2020 should bring in a larger number of new EU users than 2019 did, in part due to a medical matter, and additionally because the CRM — really, the entire momentum — is performing that well?
André Calantzopoulos
executiveYes, that is exactly what I'm telling you.
Martin King
executiveHi Adam, Martin here. Regarding IQOS heated tobacco unit share in the EU, seasonality does play a role. Take 2018, for example — you observe the same fundamental pattern, where the gain from Q2 to Q3 is fairly modest, followed by a larger gain from Q3 to Q4, and then in 2019 that same pattern shows up again. On top of that, this year we experienced a more pronounced effect, which André brought up in connection with the other news flow — but that returns us to the seasonality element. EU cigarettes will be greater since the weather is warm, people head outdoors and are able to use them more, then fewer during winter months, while with IQOS you can use it far more easily and often without concern about conditions outside, so volume shifts quarter-to-quarter aren't as visible as they are with cigarettes; thus it's genuinely cigarette seasonality that pushes these share figures to be affected.
André Calantzopoulos
executiveAll in all, Adam, what we're seeing is a pretty big jump in total user counts throughout the market. Right. And I believe that's also because we're building scale and picking up momentum. There's more word of mouth going on in these markets, and the instruments we now rely on scale better. So my hope is that this will speed up.
Adam Spielman
analystAnd then, moving on fairly quickly to Russia — clearly a really big market, and you're picking up share at a very rapid clip. Broadly put, in Q3 of last year your share stood at about 1%, and now it sits at 5%, meaning across five quarters you added four percentage points of share. So I suppose the question is whether you believe that pace can be sustained, or whether you'd anticipate it easing a bit?
André Calantzopoulos
executiveWell, to begin with, we have to make sure we're comparing like with like. Okay. Growth is still happening in the cities where we were present from the start. Obviously there's a certain amount of expansion in there, and that contributes, and room to expand remains; still, it's quite evident to me that at some point we would likely require a second price point within the Russian portfolio, since in some cities we'll be capturing the heart of the premium tier and, in a sense, a substantial chunk of the wealthier portion of the mid-price segment. Whether that's needed in 2020, I can't say, but at a minimum we must plan for 2021. Okay. That's my read on it. So a deceleration isn't what we foresee, though we do have to get ready for hitting affordability ceilings eventually in the major cities. As for the cities where we've only just launched, it's clear we've got more runway ahead of us.
Adam Spielman
analystAll right, thanks a lot.
Pamela Kaufman
analystHello there, good morning.
André Calantzopoulos
executiveGood morning, Pamela.
Martin King
executiveHello, good morning.
Pamela Kaufman
analystOver the past few years, you've put a number on how much incremental IQOS investment there was annually. What amount of additional investment do you expect for 2020 versus 2019?
André Calantzopoulos
executiveWell, from where I sit, it should be somewhat lower than 2019, and everything there is variable. Ultimately, it hinges on how many new consumers you bring in; so I'd put us somewhere between 300 and 350, subject to how many new users we get, since some costs are entirely variable. But as Martin plainly noted, on a comparable basis all of that gets offset by the savings we achieve — from cost saving initiatives. So that clearly supports margin expansion, along with the geographic mix of IQOS, which helps.
Pamela Kaufman
analystThank you. That's useful, and I was hoping to get a clearer picture of why you chose to team up with KT&G, plus how you expect their offerings to go head-to-head with IQOS. Also, since this deal broadens what you offer into e-vapor and hybrid categories, do you likewise feel there's a gap to close in modern oral?
André Calantzopoulos
executiveYes, as I've often put it, at the end of the day we won't be able to create every new product by ourselves or come up with all the inventions alone, so we welcome partnerships. The guiding idea is quite straightforward: what do we bring to the table? In my opinion, we bring technology, we bring IP that fits well, we bring the ability to do scientific assessments, and clearly the route to market. From where I stand, KT&G has an appealing offering, such as the hybrid one, which incidentally is a peripheral heated tobacco product that vaporizes at the same time. When we believe there's opportunity in particular markets and particular consumer segments, their heated tobacco offering is — ranks as the second best-performing heated tobacco product, and it also heats from the inside. I believe that using the know-how we possess, if needed, we could make this product better. And I think we choose market-by-market what the appropriate price points are for this product, so they complement our IQOS strategy. As we talked about regarding Japan, in Japan there could be some cannibalization, yet take Japan, for instance: we set two price points with our own products and saw little cannibalization. We still get far more incrementality. That's my take on it. As for the e-vapor product, we don't have significant plans right now, but we're far more interested in their hybrid and the heated tobacco, along with the team, since there's potential in those markets, and that's my view. We also have greater alignment, I'd say, broadly speaking, in Korea, which matters for the Korean market. And from a technology standpoint, we also gain access to a country such as Korea, which is among the hubs for electronics. So I think both companies come out ahead. It's a license agreement, and the financials benefit both sides. So I'm eager to work with them and grow in the right markets, giving consumers a much wider selection of products.
Pamela Kaufman
analystThanks. Could you provide an update regarding how the device price cuts and other efforts to speed up IQOS expansion in Japan have affected new user uptake there during the past year? And are you observing more heated tobacco uptake and trial among the later adopters who are harder to convert?
André Calantzopoulos
executiveWe do see a certain amount, yes. IQOS DUO should assist with that, since using it back-to-back matters for certain individuals; we tackled that issue with the multi, and now we tackle it with the main product too, and uptake is improving. Broadly speaking, pricing is also meant to eliminate all those promotions and promotional spending — we believe that represents the correct price for the product, and we constantly ready the portfolio for the next generation, which will always arrive at a premium; therefore we always cut the price of the earlier version ahead of the upcoming new version. As I've explained on many occasions, our approach involves a major innovation every 2 or 3 years plus meaningful upgrades annually across the portfolio, and that is what we're doing in Japan. So to claim there's a huge reduction — a reaction purely because we lowered device prices — it does help, but a whole combination is at work. In fact, we observe a stronger reaction in Russia, where disposable income is genuinely a problem. With the 2.4 Plus still available in the market alongside IQOS 3, plenty of consumers continue buying the 2.4, since that market is more price sensitive. I'd say the answer isn't just pricing; it's far more about continually solving the consumer pain points that block entry into the category, which is why we're focused on the current version and the one to come. That's roughly the philosophy we follow.
Pamela Kaufman
analystThanks.
Chris Growe
analystHello, and good morning.
André Calantzopoulos
executiveHello, Chris.
Chris Growe
analystHello, I wanted to ask you something, and it partly continues from a question asked previously. You mentioned that the amount you spend per user and on bringing people into IQOS is declining, and what interests me is the scale benefit you get with RRPs. Clearly, you had to lay out more cash during this year, but at the same time I'm simply attempting to grasp how that infrastructure already in place can be leveraged when you consider rolling out Platform 2 or MESH. Is much of it identical, or are many of those same resources being deployed for that purpose? My assumption is that they're included within the $300 million to $350 million figure you mentioned for this year, when you take into account what launching those new products costs.
André Calantzopoulos
executiveWell, clearly, when these new products go through the infrastructure we have — meaning our own retail, third-party retail where these sorts of franchises exist, our own digital platforms that are now established, our coaches — you're able to employ what you already have far more efficiently. So I'd say that the bulk of the spending across the year remains directed at IQOS heat-not-burn, and we expect that even once we're permitted to push IQOS on a somewhat larger scale, the cost for each user will be considerably lower, helped by the fact that explaining the category to people is no longer necessary. All we have to do is tell people how it differs and what advantages MESH offers relative to the e-vapor products that already exist; therefore no effort goes into explaining the category. In my opinion, then, it will come at a much lower cost, or be less pricey, than the heat-not-burn product.
Chris Growe
analystAll right, and thanks for addressing that. Now, moving to my next item — it ties back somewhat to a point you touched on earlier. In various EU markets, IQOS has gained share at a notably fast clip, and a few years back we discussed how in Japan, once you crossed that 2% to 2.5% mark, share gains began to speed up considerably. Have we reached that same stage across the EU? Did that show up during the fourth quarter? Some of those share gains are pretty striking. That's really my question — are we there yet, and is this happening in additional markets, or do you anticipate it spreading to more of them during 2020?
André Calantzopoulos
executiveWell, our hope is that we'll keep seeing it across a growing number of markets during 2020. Like I mentioned, we anticipate growth in user count, meaning that versus the 4 million users we had, we're expecting a figure considerably above that; so on a comparable market basis, I'd describe this as acceleration, all right. It's early in the year, we're pleased with how the fourth quarter went, and we carry solid momentum as we enter 2020. We'll continue updating you as things move forward, and this is being achieved at a far lower expense. So overall, I'd say we're assembling this quite well.
Chris Growe
analystAll right, I appreciate you taking the time.
Gaurav Jain
analystGood morning, everyone. I'd like to ask about the Canadian subsidiary. Could you update us on the current status of the RBH creditor protection talks that are taking place?
André Calantzopoulos
executiveSo, those talks are moving forward, though I'm not able to share anything further at this point. That said, a stay remains in place on all litigation, and conversations aimed at settling the matter are ongoing. As soon as there's something definite, I'll be able to provide additional information, but progress is being made.
Gaurav Jain
analystAlright, one more question about the IQOS MESH release — given that Altria revised some wording in their Juul arrangement, would you think about filing a PMTA if Juul can't stay on the market for 12 months, along with other factors?
André Calantzopoulos
executiveBefore that, I'd say we already have plenty lined up. At some point we'll likely submit a PMTA in the U.S., but a handful of P4 studies still need to be completed, since our file is similar in type to the one we pursue for IQOS, and that matters for numerous other nations too. When the time is right, we'll talk about whether and when to launch in the American market. Over the coming few months, the FDA will be extremely occupied in the U.S. with all those PMTAs. Doing anything right now doesn't strike me as the right time.
Gaurav Jain
analystAlright. If I may squeeze in one final question, could you share your thoughts on how sell-in compares with sell-through for IQOS, covering both the most recent quarter and all of 2019?
Martin King
executiveMy apologies — regarding in-market sales against shipments, or as you put it, sell-in versus sell-out, the two are roughly on par. In fact, if anything, IMS came in slightly above shipments. As a result, inventory did not shift at all over the year.
Gaurav Jain
analystAll right.
André Calantzopoulos
executiveYes, that matches what I stated at the start of the year.
Gaurav Jain
analystSure. Thanks a lot.
André Calantzopoulos
executiveOkay.
Martin King
executiveThanks.
André Calantzopoulos
executiveYes. I want to express my appreciation to everyone for being here. To start with, I'd say 2019 turned out quite well for us. We're heading into 2020 in excellent condition. We laid out the single anomaly, which is Indonesia. Let's see how that situation develops, we figure. At the start of the year, our preference is to remain careful regarding it. And then there's something currently hanging over everything — I'm referring to this entire matter involving the coronavirus. As of today, we face no difficulties. Still, it's obvious that should it keep going, travel could be affected somewhat, along with duty-free, and where the supply chain is concerned; my sense is we're sitting in fairly solid position for several weeks. Yet should it drag on for an extremely extended stretch, then just like anyone else, we might encounter certain problems regarding device supply. Now, that scenario — should this not carry on — isn't factored into our guidance for any company, but all of us are hoping for a quick resolution; so we can move past it. So, thanks once more, and I'm expecting a strong 2020.
Nick Rolli
executiveAlright, thanks a lot. That brings the call to an end. Should you have any additional questions, feel free to reach out to the Investor Relations team based here in Switzerland. Wishing you a wonderful day. Thanks.
Operator
operatorThat concludes today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.